BRPI0509276A - medicamentos de sabor disfarçado em multiparticulados de ruptura - Google Patents

medicamentos de sabor disfarçado em multiparticulados de ruptura

Info

Publication number
BRPI0509276A
BRPI0509276A BRPI0509276-0A BRPI0509276A BRPI0509276A BR PI0509276 A BRPI0509276 A BR PI0509276A BR PI0509276 A BRPI0509276 A BR PI0509276A BR PI0509276 A BRPI0509276 A BR PI0509276A
Authority
BR
Brazil
Prior art keywords
multiparticulates
disguised
rupture
coating
drugs
Prior art date
Application number
BRPI0509276-0A
Other languages
English (en)
Inventor
Leah Elizabeth Appel
Richard Frank Falk Iii
Dwayne Thomas Friesen
Sanjay Konagurthu
Edward Denis Lachapelle
Joseph Peter Reo
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0509276A publication Critical patent/BRPI0509276A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MEDICAMENTOS DE SABOR DISFARçADO EM MULTIPARTICU LADOS DE RUPTURA" Uma composição farmacêutica compreende multiparticulados compreendendo um medicamento, um material matriz, e agente de intumescimento. Em um aspecto, os multiparticulados compreendem um núcleo compreendendo um medicamento, e um revestimento ao redor do núcleo. O revestimento é selecionado do grupo consistindo em (1) um revestimento substancialmente impermeável ao medicamento e permeável à água, e (ii) um revestimento antientérico.
BRPI0509276-0A 2004-04-12 2005-04-06 medicamentos de sabor disfarçado em multiparticulados de ruptura BRPI0509276A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56159504P 2004-04-12 2004-04-12
PCT/IB2005/000917 WO2005097064A2 (en) 2004-04-12 2005-04-06 Taste-masked drugs in rupturing multiparticulates

Publications (1)

Publication Number Publication Date
BRPI0509276A true BRPI0509276A (pt) 2007-09-04

Family

ID=35125594

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509276-0A BRPI0509276A (pt) 2004-04-12 2005-04-06 medicamentos de sabor disfarçado em multiparticulados de ruptura

Country Status (9)

Country Link
US (1) US8236349B2 (pt)
EP (1) EP1737433B1 (pt)
JP (1) JP2007532623A (pt)
AT (1) ATE378042T1 (pt)
BR (1) BRPI0509276A (pt)
CA (1) CA2561855A1 (pt)
DE (1) DE602005003343T2 (pt)
MX (1) MXPA06011765A (pt)
WO (1) WO2005097064A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1810668A1 (en) * 2006-01-23 2007-07-25 LEK Pharmaceuticals D.D. Coated formulations containing tolterodine tartrate
US8716200B2 (en) 2006-09-13 2014-05-06 Ecolab Usa Inc. Conveyor lubricants including emulsion of a lipophilic compound and an emulsifier and/or an anionic surfactant and methods employing them
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
EP2067469A1 (en) 2007-11-06 2009-06-10 Teva Pharmaceutical Industries Ltd. Chewable formulations
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AU2010325746B2 (en) 2009-12-02 2016-02-25 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them
EP2515879A4 (en) * 2009-12-22 2014-04-02 Fmc Corp Inc FINE PARTICLE CROSCARMELLOSIS AND USES THEREOF
WO2011110939A2 (en) 2010-03-11 2011-09-15 Rubicon Research Private Limited Pharmaceutical compositions of substituted benzhydrylpiperazines
KR20250150154A (ko) 2016-03-15 2025-10-17 에이서 테라퓨틱스 인크. 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도
WO2018035030A1 (en) * 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
WO2019039420A1 (ja) 2017-08-21 2019-02-28 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
JP7271869B2 (ja) * 2018-07-25 2023-05-12 ニプロ株式会社 レボセチリジン含有錠剤
JP2020015690A (ja) * 2018-07-25 2020-01-30 ニプロ株式会社 レボセチリジン含有錠剤
WO2021255645A1 (en) 2020-06-18 2021-12-23 Capsugel Belgium Nv Method for making multiparticulates from a liquid feed employing a spinning disc sprayer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1266827A (en) * 1984-06-20 1990-03-20 Merck & Co., Inc. Controlled porosity osmotic pump
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
NZ226179A (en) * 1987-09-24 1991-04-26 Merck & Co Inc Controlled porosity osmotic pump for sustained release of pharmaceutical agents
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
DE3838094A1 (de) * 1988-11-10 1990-05-17 Nordmark Arzneimittel Gmbh Feste pharmazeutische retardform
US5190760A (en) * 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
WO1991004757A1 (en) 1989-10-02 1991-04-18 Cima Labs, Inc. Effervescent dosage form and method of administering same
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5336433A (en) * 1992-06-08 1994-08-09 Eka Nobel Ab Bleaching agent
WO1994001093A1 (en) * 1992-07-09 1994-01-20 Merck & Co., Inc. Controlled porosity osmotic enalapril pump
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
WO1995003785A1 (en) 1993-08-03 1995-02-09 Warner-Lambert Company Pleasant tasting effervescent cold/allergy medications
US5518801A (en) 1993-08-03 1996-05-21 The Procter & Gamble Company Web materials exhibiting elastic-like behavior
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
US5914134A (en) * 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
DE19809719A1 (de) * 1998-03-06 1999-09-09 Roehm Gmbh Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen
EP1900283A3 (en) * 1998-03-23 2010-02-10 General Mills, Inc. Encapsulation of components into edible products
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
US6086920A (en) * 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
AU773555B2 (en) * 1999-07-09 2004-05-27 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical liquid formulations
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
KR20020062323A (ko) * 1999-12-06 2002-07-25 펜웨스트 파머슈티칼즈 컴파니 제약학적 초붕해제
DK1248594T3 (da) 2000-01-19 2006-02-06 Mannkind Corp Formulering med multi-spidsfrigivelse til indgivelse af lægemidler
ES2284643T3 (es) 2000-04-20 2007-11-16 Novartis Ag Composicion de revestimiento enmascarante del sabor.
US20040026546A1 (en) * 2000-04-26 2004-02-12 Czekai David A Apparatus for sanitary wet milling
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
CA2554012A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects

Also Published As

Publication number Publication date
CA2561855A1 (en) 2005-10-20
DE602005003343D1 (de) 2007-12-27
US8236349B2 (en) 2012-08-07
MXPA06011765A (es) 2006-12-15
EP1737433B1 (en) 2007-11-14
US20070196483A1 (en) 2007-08-23
JP2007532623A (ja) 2007-11-15
WO2005097064A3 (en) 2006-08-03
DE602005003343T2 (de) 2008-09-11
WO2005097064A2 (en) 2005-10-20
EP1737433A2 (en) 2007-01-03
ATE378042T1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
BRPI0509276A (pt) medicamentos de sabor disfarçado em multiparticulados de ruptura
ECSP034869A (es) Una composicion para la piel, permeable selectiva inhibidora de ciclooxigenasa-2
BRPI0513300A (pt) forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol
BRPI0606883A2 (pt) composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
MXPA03012041A (es) Sistema de administracion controlada de farmacos de retencion gastrica.
IS7076A (is) Bólusetning með einföldum skammti af Mycoplasma hyopneumoniae, og notkun efnisins í lækningaskyni
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
IL179714A (en) Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation
WO2006022996A3 (en) Dosage form containing multiple drugs
EE04997B1 (et) Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine
ECSP045171A (es) Régimen de dosificación y composición farmacéutica para anticoncepción de emergencia
WO2006050155A3 (en) Cancer therapeutic compositions
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
WO2007075475A3 (en) Gastric reflux resistant dosage forms
DE60318447D1 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
SG152257A1 (en) Topical preparation containing ambroxol
IL177243A0 (en) Extended release coated minitablets of venlafaxine hydrochloride
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
JP2003528919A5 (pt)
NO323466B1 (no) Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater
BR0212989A (pt) Métodos para tratamento neuroprotetor usando inibidores de inos seletivos
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
IS6317A (is) Efni og lyf til að koma í veg fyrir endaþarms- og/eða ristilskrabbamein

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]